慢性阻塞性肺疾病与曲霉感染的复杂交互及全球健康意义
综述指出曲霉是COPD患者常见肺部真菌病原,因气道防御受损可致持续感染、过敏及慢性或侵袭性肺曲霉病;反复急性加重者气道检出曲霉更常见,但培养敏感性低、诊断手段应用不足,减少皮质类固醇暴露或为关键干预点。
要点
- COPD患者气道曲霉检出与反复急性加重相关,提示未评估的治疗机会。
- 痰培养敏感性低、支气管镜风险高,血清IgG和抗原检测应用不足。
- 减少皮质类固醇暴露可能大幅降低曲霉对COPD患者的影响。
核心结论
- COPD与曲霉存在复杂交互,曲霉感染显著被低估,减少皮质类固醇暴露或可减轻其影响。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- COPD患者对曲霉的常见防御不同程度受损,可导致持续气道感染(尤其伴支气管扩张)、过敏或致敏及可能的气道阻力增加、慢性或侵袭性肺曲霉病。
- 气道检出曲霉的COPD患者反复急性加重更常见。
- 室内潮湿或霉变、较高空气污染指数及呼吸道病毒感染可加重该负性交互,全身和口服皮质类固醇进一步损害气道和肺部防御。
关键数值与推荐
- 痰培养曲霉敏感性差,支气管镜对慢性呼吸功能受损患者可能有害,诱导痰仅用于研究,血清曲霉IgG和抗原检测作用未被认识。
- 对住院及高风险患者,痰液高通量真菌培养和曲霉PCR可使更多诊断成立。
临床怎么用
- 对COPD急性加重患者应关注曲霉感染可能,考虑痰液高通量真菌培养和PCR以助诊断。
- 减少COPD患者皮质类固醇暴露可能降低曲霉感染影响。
局限性
- 摘要未报告综述的检索范围及纳入研究细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aspergillus spp are common airborne fungi, and the commonest fungal pathogen of human lungs. In patients with chronic obstructive pulmonary disease (COPD), the usual defences against disease are impaired to various degrees, leading to persistent airway infection, especially with bronchiectasis; allergy (or sensitisation) and probable additional airways resistance; and chronic pulmonary aspergillosis or invasive aspergillosis. Recurrent COPD exacerbations are more common in those with Aspergillus found in the airways, opening up an unassessed therapeutic opportunity to reduce hospital admissions and deaths. External factors worsening the effect of this negative interaction include damp and/or mould in homes, higher air pollution indices. and respiratory viral infections that abrogate key immune defences. Corticosteroid therapy, both systemic and oral, further impairs airway and lung defences. Both local and general immune responses are affected. Aspergillus infection in patients with COPD is markedly under-recognised, primarily because the sensitivity of culture of Aspergillus from sputum is poor, bronchoscopy can be harmful in patients with chronic respiratory impariment, induced sputum is only used in research studies, and the role of serum Aspergillus IgG and antigen testing is not appreciated. In hospitalised patients and those at higher risk, high-volume fungal culture and PCR for Aspergillus on sputum would enable many more diagnoses. With approximately 60 million patients with COPD hospitalised with exacerbations globally, and high mortality rates in both invasive and chronic pulmonary aspergillosis in those with COPD, many opportunities for prevention, earlier diagnosis, and therapeutic interventions are untested. Reducing corticosteroid exposure in patients with COPD could greatly reduce the impact of Aspergillus in patients with COPD.
引用
- Denning DW, Bertuzzi M, Chotirmall SH, et al. COPD and Aspergillus-a complex interaction of global health importance. Lancet Infect Dis. 2026. PMID: 42612667. doi:10.1016/S1473-3099(26)00360-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。